미국의 반려동물용 심장 의약품 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 의약품별, 동물 유형별, 적응증별, 최종 용도별, 유통 채널별, 부문 예측(2025-2033년)

Market Size & Trends:

The U.S. companion animal cardiac pharmaceuticals market size was estimated at USD 776.29 million in 2024 and is projected reach USD 1,499.52 million by 2033, growing at a CAGR of 7.76% from 2025 to 2033. The key factors responsible for driving the market growth include the rising incidence of heart diseases in pets, increasing pet health expenditure, and increasing research and development.

For instance, according to an article published by Small Door Inc., Congestive heart failure (CHF) is relatively prevalent in dogs, affecting around 10% of the overall canine population and as many as 75% of older dogs who suffer from some form of heart disease.

The growing incidence of heart disease among companion animals is becoming a key driver in expanding veterinary cardiology services. As pets live longer due to general veterinary care, nutrition, and lifestyle improvements, they are more likely to develop chronic age-related conditions such as cardiovascular diseases. Veterinarians are increasingly diagnosing conditions such as valvular diseases, cardiomyopathies, and arrhythmias, which require specialized knowledge and treatment.

Veterinary cardiology has witnessed significant advancements in recent years, transforming how heart conditions in animals are diagnosed and treated. Innovations in diagnostic tools, surgical techniques, and therapeutic options are enhancing the precision of care and improving the outcomes and quality of life for pets. For instance, in April 2025, Auburn University's College of Veterinary Medicine performed a groundbreaking surgery on Hashbrown, a kitten with supravalvular mitral stenosis. This hybrid balloon valvuloplasty, a first-of-its-kind procedure for such a small and young patient, involved a collaborative effort by professionals.

The rise in innovative treatments and the increasing awareness of the importance of heart health in pets is driving growth in the veterinary cardiology industry. Pet owners increasingly seek specialized care for their animals, recognizing the availability of life-extending treatments that were once only accessible to humans. As a result, the demand for advanced veterinary cardiology services is expected to grow, further solidifying its place as a crucial component of modern veterinary medicine.

For example, in June 2024, the Indian Council for Agricultural Research published a study examining the incidence of cardiac arrhythmias in 435 dogs with a history of generalized diseases over 14 months from July 2022 to September 2023. The assessment was aimed to determine the occurrence of arrhythmias and found that 114 dogs (26.21%) displayed various types, including atrial fibrillation (30.70%), ST-segment coving, sinus arrest (9.65% each), and ST-segment elevation (8.77% each).

U.S. Companion Animal Cardiac Pharmaceuticals Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal cardiac pharmaceuticals market report based on pharmaceuticals, animal type, indication, end use, and distribution channel.

• Pharmaceuticals Outlook (Revenue, USD Million, 2021 - 2033)
• Pimobendan
• Spironolactone and Benazepril Hydrochloride
• Others
• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Horses
• Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Congestive Heart Failure
• Myocardial (Heart Muscle) Disease
• Arrhythmias
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• Others
• Distribution Channel (Revenue, USD Million, 2021 - 2033)
• Hospital/ Clinic Pharmacy
• Retail
• E-Commerce

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Cardiac Pharmaceuticals Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of heart diseases in pets
    • 3.2.1.2. Advancements in veterinary medicine
    • 3.2.1.3. Increasing research & development
    • 3.2.1.4. Increasing adoption of pet insurance
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of treatment
    • 3.2.2.2. Lack of skilled professionals
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Pricing Analysis
  • 3.3.5. Pet ownership Demographics
  • 3.3.6. Estimated pet Population by key countries, key species, 2024

Chapter 4. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Movement Analysis
• 4.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by pharmaceuticals, 2021 to 2033 (USD Million)
• 4.4. Pimobendan
  • 4.4.1. Pimobendan Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Spironolactone and benazepril hydrochloride
  • 4.5.1. Spironolactone and benazepril hydrochloride Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal type Movement Analysis
• 5.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Animal type, 2021 to 2033 (USD Million)
• 5.4. Dogs
  • 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cats
  • 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Horses
  • 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Movement Analysis
• 6.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 6.4. Congestive Heart Failure
  • 6.4.1. Congestive Heart Failure Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Myocardial (Heart Muscle) Disease
  • 6.5.1. Myocardial (Heart Muscle) Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Arrhythmias
  • 6.6.1. Arrhythmias Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Movement Analysis
• 7.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by end use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Hospitals & Clinics
    • 7.3.1.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Others
    • 7.3.2.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Movement Analysis
• 8.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 8.3.1. Hospital/ Clinic Pharmacy
    • 8.3.1.1. Hospital/ Clinic Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. Retail
    • 8.3.2.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. E-Commerce
    • 8.3.3.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heap Map Analysis
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim International Gmbh
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Elanco
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Merck & Co., Inc.
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Dechra Pharmaceuticals PLC
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Ceva Sante Animale
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Phibro Animal Health Corporation
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Virbac
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Bimeda Corporate
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Biogenesis Bago
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Application launch
  • 9.4.4. Others
• 9.5. List of other key players